What happened
ClinicalTrials.gov registry update for Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
SourceClinicalTrials.govclinical updateBiotech
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Clinical/translation signal: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Factual summary
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
SourceClinicalTrials.govLimitations
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
SourceClinicalTrials.govLinked output
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)clinical trialPeople
No reviewed person relationship is attached to this event.
Organizations
Topics
No reviewed topic relationship is attached to this event.
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060)
Timeline
- clinical updateTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)